Familial Adenomatous Polyposis - A Pipeline Analysis Report

Overview of the drug development pipeline for familial adenomatous polyposis

Familial adenomatous polyposis (FAP) is an inherited disorder, which causes extra tissue formation in the colon or large intestine and later forms cancer in the colon. FAP is an inherited situation leading to the development of additional tissues known as polyps, in the large intestine. Polyps can also form in the upper gastrointestinal tract, especially in the upper part of the small intestine. If FAP is not treated in the early ages, it can become cancerous. The milder form of FAP is called attenuated familial adenomatous polyposis (AFAP), in which the growth of polyps is slow. The companies are forming strategic exclusive agreements or are acquiring other companies. For instance, companies including Tillotts Pharma and Sucampo Pharmaceuticals entered into exclusive licensing agreements with Cancer Prevention Pharmaceuticals, thereby helping Cancer Prevention Pharmaceuticals in developing and commercializing its drug candidate in Europe, Japan, and North America for the treatment of FAP. Consequently, the rising incidences of this condition is expected to promote the drug development for familial adenomatous polyposis.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for familial adenomatous polyposis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of familial adenomatous polyposis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Cancer Prevention Pharmaceuticals
• Marina Biotech
• RMX Biopharma
• Stem Synergy Therapeutics

Therapeutic assessment of the drug development pipeline for familial adenomatous polyposis by route of administration

• Oral

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for familial adenomatous polyposis by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the the molecules that are currently in the drug development pipeline for familial adenomatous are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for familial adenomatous polyposis?
• What are the companies that are currently involved in the development of drug molecules for familial adenomatous polyposis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.